SCM
CRBP icon

Silverarc Capital Management’s Corbus Pharmaceuticals CRBP Stock Holding History

Silverarc Capital Management’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-17,800
Closed -$367K – 72
2024
Q3 		$367K Buy
+17,800
New +$911K 0.08% 67

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Silverarc Capital Management's CRBP Position: Q3 2024 in Review

Silverarc Capital Management sold out of Corbus Pharmaceuticals (CRBP) in Q3 2024, closing a stake of 172,492 shares — an estimated $8.83M sold.

Silverarc Capital Management first reported a position in CRBP in Q1 2024 and held it in 2 quarters. The position peaked at $7.81M in Q2 2024. 107 funds tracked by Wall St. Rank hold CRBP as of Q3 2024.

  • Silverarc Capital Management reported no remaining Corbus Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Silverarc Capital Management sold 172,492 Corbus Pharmaceuticals shares in Q3 2024, an estimated $8.83M.
  • Silverarc Capital Management first reported a position in Corbus Pharmaceuticals in Q1 2024 and held it in 2 quarters.
  • Silverarc Capital Management's Corbus Pharmaceuticals position peaked at $7.81M in Q2 2024.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q3 2024.

Based on Silverarc Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.